AU2019214048B2 - Nitrogenated heterocyclic amide compound, and use thereof for medical purposes - Google Patents

Nitrogenated heterocyclic amide compound, and use thereof for medical purposes Download PDF

Info

Publication number
AU2019214048B2
AU2019214048B2 AU2019214048A AU2019214048A AU2019214048B2 AU 2019214048 B2 AU2019214048 B2 AU 2019214048B2 AU 2019214048 A AU2019214048 A AU 2019214048A AU 2019214048 A AU2019214048 A AU 2019214048A AU 2019214048 B2 AU2019214048 B2 AU 2019214048B2
Authority
AU
Australia
Prior art keywords
compound
formula
pharmaceutically acceptable
acceptable salt
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019214048A
Other languages
English (en)
Other versions
AU2019214048A1 (en
Inventor
Masayuki KOTOKU
Takaki MAEBA
Ritsuki Masuo
Dai Motoda
Koichi Suzawa
Nobutaka YAMAOKA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Publication of AU2019214048A1 publication Critical patent/AU2019214048A1/en
Application granted granted Critical
Publication of AU2019214048B2 publication Critical patent/AU2019214048B2/en
Assigned to SHIONOGI & CO., LTD. reassignment SHIONOGI & CO., LTD. Request to Amend Deed and Register Assignors: JAPAN TOBACCO INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
AU2019214048A 2018-02-01 2019-01-30 Nitrogenated heterocyclic amide compound, and use thereof for medical purposes Active AU2019214048B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018016328 2018-02-01
JP2018-016328 2018-02-01
PCT/JP2019/003052 WO2019151274A1 (ja) 2018-02-01 2019-01-30 含窒素複素環アミド化合物及びその医薬用途

Publications (2)

Publication Number Publication Date
AU2019214048A1 AU2019214048A1 (en) 2020-06-25
AU2019214048B2 true AU2019214048B2 (en) 2023-03-16

Family

ID=67479787

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019214048A Active AU2019214048B2 (en) 2018-02-01 2019-01-30 Nitrogenated heterocyclic amide compound, and use thereof for medical purposes

Country Status (21)

Country Link
US (4) US10800784B2 (enExample)
EP (1) EP3747888A4 (enExample)
JP (3) JP7241556B2 (enExample)
KR (1) KR102725118B1 (enExample)
CN (1) CN111655692B (enExample)
AR (1) AR114237A1 (enExample)
AU (1) AU2019214048B2 (enExample)
BR (1) BR112020014177A2 (enExample)
CA (1) CA3090219A1 (enExample)
CL (1) CL2020002003A1 (enExample)
CO (1) CO2020009420A2 (enExample)
IL (1) IL276386B2 (enExample)
MX (1) MX2020008126A (enExample)
MY (1) MY205011A (enExample)
PE (1) PE20211273A1 (enExample)
PH (1) PH12020500613A1 (enExample)
SA (1) SA520412473B1 (enExample)
SG (1) SG11202006916SA (enExample)
TW (1) TWI803570B (enExample)
WO (1) WO2019151274A1 (enExample)
ZA (1) ZA202004548B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3851103A4 (en) 2018-09-11 2022-06-08 Japan Tobacco Inc. THERAPEUTIC OR PROPHYLACTIC AGENT FOR CHRONIC KIDNEY DISEASE CONTAINING A PYRAZOLE-AMIDE COMPOUND
WO2023032940A1 (ja) 2021-09-01 2023-03-09 日本たばこ産業株式会社 含窒素三環性化合物及びその医薬用途
CN110407744A (zh) * 2019-08-13 2019-11-05 上海毕得医药科技有限公司 一种1-(4-氨基吡啶-2-基)乙酮的合成方法
PT4097099T (pt) 2020-02-07 2024-07-19 Gasherbrum Bio Inc Agonistas heterocíclicos de glp-1
BR112022014749A2 (pt) * 2020-03-04 2022-10-11 Japan Tobacco Inc Composto tricíclico fundido e uso medicinal do mesmo
WO2022052958A1 (en) * 2020-09-10 2022-03-17 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
AU2022244941B2 (en) * 2021-03-23 2024-08-01 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Heterocycle substituted ketone derivative, and composition and medicinal use thereof
KR20250168210A (ko) 2023-02-16 2025-12-02 가셔브룸 바이오, 인크. 헤테로시클릭 glp-1 효능제

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015002119A1 (ja) * 2013-07-01 2015-01-08 日本たばこ産業株式会社 ピラゾール－アルコール化合物およびその医薬用途
WO2017020981A1 (en) * 2015-07-31 2017-02-09 Merck Patent Gmbh Bicyclic heterocyclic derivatives

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7943617B2 (en) * 2006-11-27 2011-05-17 Bristol-Myers Squibb Company Heterobicyclic compounds useful as kinase inhibitors
WO2008132162A1 (en) * 2007-04-26 2008-11-06 Boehringer Ingelheim International Gmbh 3- (sulphonylamino) -phenyl-2 -hydroxy-ethylamino derivatives useful as beta-agonists, processes for preparing them and their use as medicaments
AU2008263206A1 (en) * 2007-06-01 2008-12-18 Schering Corporation Gamma secretase modulators
EP2090576A1 (en) * 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators
AR074797A1 (es) * 2008-10-10 2011-02-16 Japan Tobacco Inc Compuesto de fluoreno , composiciones farmaceuticas , inhibidores de pdhk y pdhk2 , metodos de tratamiento , usos de los mismos y kit comercial
MX364602B (es) * 2011-06-27 2019-05-02 Alectos Therapeutics Inc Inhibidores selectivos de glicosidasa y usos de los mismos.
CA2855009C (en) * 2011-11-15 2019-07-09 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds useful as gpr119 agonists
WO2013187646A1 (en) * 2012-06-12 2013-12-19 Chong Kun Dang Pharmaceutical Corp. Piperidine derivatives for gpr119 agonist
CN103570725B (zh) 2012-08-01 2017-03-22 中国科学院上海药物研究所 哌嗪并三唑类化合物及其制备方法和用途
TWI633885B (zh) * 2013-03-15 2018-09-01 日商日本煙草產業股份有限公司 吡唑－醯胺化合物及其醫藥用途
TW201536748A (zh) * 2013-07-01 2015-10-01 Japan Tobacco Inc 茀－醯胺化合物及其醫藥用途
GB201316823D0 (en) * 2013-09-23 2013-11-06 R & D Vernalis Ltd New Chemical Entities
CA2933927C (en) 2013-12-17 2021-11-16 Merck Patent Gmbh N1-(3,3,3-trifluoro-2-hydroxo-2-methylpropionyl)-piperidine derivatives as inhibitors of pyruvate dehydrogenase kinase
EP3436443B1 (en) 2016-03-29 2020-03-11 Merck Patent GmbH N1-(3,3,3-trifluoro-2-hydroxy-2-methylpropionyl)-piperidine derivatives as inhibitors of pyruvate dehydrogenase kinase
CN109071490B (zh) * 2016-04-28 2021-04-06 默克专利股份公司 哌啶基衍生物
EP3492452B1 (en) * 2016-07-29 2022-08-31 Japan Tobacco Inc. Production method for pyrazole-amide compound
US10414774B2 (en) 2016-08-15 2019-09-17 Merck Sharp & Dohme Corp. Compound useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolc disease
LT3532064T (lt) 2016-10-28 2020-09-25 H. Lundbeck A/S Kompleksiniai gydymai, apimantys imidazopirazonus, skirti psichiatrinių ir (arba) kognityvinių sutrikimų gydymui
RU2019108717A (ru) 2016-10-28 2020-11-30 Х. Лундбекк А/С Комбинированные средства для лечения, предусматривающего введение имидазопиразинонов
WO2023032940A1 (ja) * 2021-09-01 2023-03-09 日本たばこ産業株式会社 含窒素三環性化合物及びその医薬用途
BR112022014749A2 (pt) * 2020-03-04 2022-10-11 Japan Tobacco Inc Composto tricíclico fundido e uso medicinal do mesmo

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015002119A1 (ja) * 2013-07-01 2015-01-08 日本たばこ産業株式会社 ピラゾール－アルコール化合物およびその医薬用途
WO2017020981A1 (en) * 2015-07-31 2017-02-09 Merck Patent Gmbh Bicyclic heterocyclic derivatives

Also Published As

Publication number Publication date
CL2020002003A1 (es) 2020-10-23
JP2023071925A (ja) 2023-05-23
JP2024116307A (ja) 2024-08-27
MX2020008126A (es) 2020-09-18
RU2020128593A (ru) 2022-03-03
WO2019151274A1 (ja) 2019-08-08
SA520412473B1 (ar) 2023-02-12
KR102725118B1 (ko) 2024-11-04
MY205011A (en) 2024-09-27
PH12020500613A1 (en) 2021-05-31
CA3090219A1 (en) 2019-08-08
US20260070910A1 (en) 2026-03-12
SG11202006916SA (en) 2020-08-28
PE20211273A1 (es) 2021-07-19
AU2019214048A1 (en) 2020-06-25
AR114237A1 (es) 2020-08-05
JP2019131544A (ja) 2019-08-08
CO2020009420A2 (es) 2020-08-10
CN111655692B (zh) 2023-10-10
US20200017505A1 (en) 2020-01-16
EP3747888A1 (en) 2020-12-09
US10800784B2 (en) 2020-10-13
JP7241556B2 (ja) 2023-03-17
US20210284644A1 (en) 2021-09-16
EP3747888A4 (en) 2021-12-15
TW201934553A (zh) 2019-09-01
US20240300952A1 (en) 2024-09-12
KR20200115566A (ko) 2020-10-07
CN111655692A (zh) 2020-09-11
IL276386B2 (en) 2023-06-01
ZA202004548B (en) 2021-10-27
IL276386A (en) 2020-09-30
BR112020014177A2 (pt) 2020-12-08
TWI803570B (zh) 2023-06-01

Similar Documents

Publication Publication Date Title
AU2019214048A1 (en) Nitrogenated heterocyclic amide compound, and use thereof for medical purposes
JP2022071046A (ja) Ｗｄｒ５タンパク質－タンパク質結合の阻害剤
EP2691399B1 (en) Thiazolopyrimidine compounds
JP5520377B2 (ja) Ｊａｋの三環系阻害剤
EP2742049A1 (en) Tricyclic heterocyclic compounds and jak inhibitors
JP2010132689A (ja) ジヒドロピラゾロピリミジノン誘導体
EP2475667A1 (en) Inhibitors of jak
JP2013533868A (ja) タンパク質チロシンキナーゼ阻害剤としての新規ホモピペラジン誘導体およびそれらの医薬使用
JP2019507179A (ja) Ｗｄｒ５タンパク質−タンパク質結合の阻害剤
JP2023519666A (ja) Ｇｐｒ５２モジュレーター化合物
CA3166747A1 (en) Fused tricyclic compound and medicinal use thereof
AU2022337617A1 (en) Nitrogen-containing tricyclic compound and pharmaceutical use thereof
RU2789670C2 (ru) Азотсодержащий гетероциклический амид и его применение для медицинских целей
HK40041663A (en) Nitrogenated heterocyclic amide compound, and use thereof for medical purposes
JP7618898B1 (ja) ヒト呼吸器合胞体ウイルス及びメタニューモウイルスの阻害薬
TW202122386A (zh) 經取代的1,3-苯基雜芳基衍生物及其在治療疾病中之用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: SHIONOGI & CO., LTD.

Free format text: FORMER NAME(S): JAPAN TOBACCO INC.